Anthony Johnson

Company: Goldfinch Bio

Job title: President & Chief Executive Officer

Seminars:

Panel Discussion: Challenges & Opportunities in Drug Development for Rare Kidney Diseases 3:30 pm

Incorporating clinical outcome assessments in trials Benefits of orphan drug designation and potential accelerated approval pathways in rare renal diseases Partnering with patient advocacy groups and registries in recruiting rare kidney disease patient populationsRead more

day: Day One

Leveraging a Precision Medicine Approach to Inform Future Directions of Drug Development in CKD 12:00 pm

Reflecting on recent progress: what has been achieved so far? Applying lessons in biomarkers and clinical trial innovation to CKD drug development Looking to the future: paving the way for pipeline progression and new therapiesRead more

day: Track 2 - Day 1 AM